Cytokine-targeted treatments have the potential to significantly enhance clinical outcomes in myocarditis and inflammatory cardiomyopathy by modifying the inflammatory response.
Do cytokine-targeted treatments improve clinical outcomes and are they safe in patients with myocarditis or inflammatory cardiomyopathy?
Cytokine-targeted therapies show potential for improving outcomes in myocarditis and inflammatory cardiomyopathy, but require careful monitoring for infectious and autoimmune complications.
Abstract The purpose of this article is to assess the safety and effectiveness of cytokine-targeted treatments for inflammatory cardiomyopathy and myocarditis. Clinical trials, case studies, and observational studies that have been published in the past 10 years and particularly look into the use of cytokine inhibitors, such as small molecule inhibitors and monoclonal antibodies, in patients with myocarditis or inflammatory cardiomyopathy are included in the inclusion criteria. Investigations with insufficient cytokine targeting data, non-human investigations, and reviews without original data are among the exclusion criteria. The analysis comes to the conclusion that cytokine-targeted treatments have the potential to significantly enhance clinical outcomes in a number of studies by modifying the inflammatory response in myocarditis and inflammatory cardiomyopathy. However, cautious patient selection and monitoring are required due to the possibility of side effects, including infections and autoimmune problems. To maximize patient outcomes, future research should concentrate on finding biomarkers to forecast drug response and creating individualized treatment plans.
Omar Elsaka (Wed,) conducted a review in Myocarditis and inflammatory cardiomyopathy. Cytokine-targeted treatments was evaluated on Clinical outcomes. Cytokine-targeted treatments have the potential to significantly enhance clinical outcomes in myocarditis and inflammatory cardiomyopathy by modifying the inflammatory response.